SELB

Selecta Biosciences

Last Updated:

Q3'20

Price

quotes and stock data delayed 15 minutes

Cash

$146.3M

Burn Rate (Qtr)

-$9.7M

Company Profile

Selecta Biosciences is a clinical-stage biotechnology company with an unrelenting commitment to overcoming immunogenicity with our pioneering ImmTOR immune tolerance platform. At our core, we are problem-solvers dedicated to transforming the lives of patients and their families who struggle with serious and debilitating diseases.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Recent Posts

See what the community is saying - click to see full post

What has caused SELB's runup in 2020? Isn't the COMPARE trial testing the wrong control?

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon